Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular adenosine formation in humans in vivo

Completed

• Conditions: blood flow; ischemia reperfusion injury; 10011082

• Registration Number: NL-OMON38928
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2013-12-24
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 14

Inclusion Criteria

Healthy, male, age 18-40 years, written informed consent
(see also chapter 4.2 (Inclusion criteria) of the protocol)

Exclusion Criteria

smoking, history of cardiovascular disease, hypertension, renal dysfunction, serum potassium > 4.7 mmol/L
(see also chapter 4.3 (Exclusion criteria) of the protocol)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-To study whether the MR antagonist eplerenone activates CD73 and hereby<br /><br>increases extracellular formation of adenosine in humans in vivo, by using the<br /><br>forearm vasodilator response to the intrabrachial administration of the<br /><br>ENT-inhibitor dipyridamole, as a surrogate for adenosine receptor stimulation.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-To study whether eplerenone increases adenosine formation, by measuring<br /><br>forearm blood flow to incremental periods of arterial occlusion, as an<br /><br>endogenous stimulus for adenosine upregulation. </p><br>